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Abstract: Chemokines are proinflammatory chemoattractant cyto-
kines that regulate cell trafficking and adhesion. The CXCR4 che-
mokine receptor and its ligand, stromal cell derived factor (SDF-1),
constitute a chemokine/receptor axis that has attracted great interest
because of an increasing understanding of its role in cancer, includ-
ing lung cancer. The CXCR4/SDF-1 complex activates several
pathways that mediate chemotaxis, migration and secretion of an-
giopoietic factors. Neutralization of SDF-1 by anti-SDF-1 or anti-
CXCR4 monoclonal antibody in preclinical in vivo studies results in
a significant decrease of non-small cell lung cancer metastases.
Since anti-SDF-1/CXCR4 strategies have already been developed
for use in combating human immunodeficiency virus infections, it is
likely that these approaches will be used in clinical trials in non-
small cell lung cancer in the very near future.
Key Words: CXCR4, SDF-1, Non-small cell lung cancer, Chemo-
kines, Metastasis, Migration.
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Lung cancer has been the leading cause of cancer deathworldwide for many decades. Despite this sobering statis-
tic and years of research, treatments that meaningfully change
the natural history of lung cancer remain elusive. Because
metastatic spread constitutes the primary source of morbidity
and mortality, a thorough understanding of the metastatic
process is likely to be crucial to developing effective new
therapies for lung cancer. Recently, a growing appreciation of
the role of chemokines in cancer has unlocked the secrets of
some of the molecular pathways underpinning this process,
creating an understanding that reflects Paget’s “seed and soil
hypothesis” and which may lead to new approaches to lung
cancer management. This brief review focuses on one such
chemokine receptor axis, namely the CXCR4 and SDF-1
axis, and its emerging role in non-small cell lung cancer
(NSCLC).
Chemokines, a class of small (8–14 kDa) proinflam-
matory chemoattractant cytokines,1 are the major regulators
of cell trafficking and adhesion in the body.2 Chemokines
bind and activate a subset of seven transmembrane spanning
G protein coupled receptors present on the surface of target
cells.3 They play a crucial role in the host immune defense
system by recruiting specific leukocyte subpopulations to
sites of tissue damage and infection, and are highly up-
regulated by inflammatory stimuli such as antigens, poly-
clonal stimulants, cell irritants, and cytokines.4,5 Chemokines
also have a role in dendritic cell maturation, B and T cell
development, T cell responses, infection response and angio-
genesis. Most intriguing is the accumulating evidence point-
ing to their role in tumor growth and metastasis.1
Basic Biology of the CXCR4/SDF-1 Axis
The CXCR4 chemokine receptor and its ligand, stromal
cell derived factor (SDF-1), constitute a chemokine/receptor
axis that has attracted great interest partly because CXCR4 is
a target for Human Immunodeficiency Virus (HIV) binding
and entry into cells,6,7 but also because of an increasing
understanding of its role in cancer. CXCR4, although initially
cloned from leukocytes,8 is now known to be expressed by
many cell types and has a role in multiple facets of cellular
movement.9 Its ligand, SDF-1 (also called CXCL12), a mem-
ber of the alpha family of chemokines,1 was initially isolated
from a bone marrow stromal cell line10 and is a potent
lymphocyte chemoattractant.11 However, SDF-1 is also con-
stitutively secreted by fibroblasts in several different organs/
tissues including bone marrow, lymph nodes, lung, liver, and
muscle.12,13 During embryogenesis the CXCR4/SDF-1 axis is
involved in both hematopoiesis and organogenesis as dem-
onstrated by knock-out studies.12,14–16 Later, the CXCR4/
SDF-1 axis plays a critical role in the homing and retention of
hematopoietic/lymphopoietic stem cells, pre T and B lym-
phocytes in the bone marrow,17,18 and the trafficking of these
cells to sites of tissue inflammation and damage.11,19 Both
CXCR4 and SDF-1 can be up-regulated under certain condi-
tions, especially in response to hypoxic stimuli. CXCR420
and SDF-121 gene expression are up-regulated in response to
hypoxia inducible factor-1 (HIF-1) in endothelial cells and
in tumor cells in response to both HIF-120,22 and NF-B.23
Significantly, it has been shown that activated epidermal
growth factor receptor also increases the expression of
CXCR4 in lung cancer tumor cells.22 Although it had been
thought that SDF-1 bound exclusively to CXCR4, and
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CXCR4 had SDF-1 as its only ligand,24 there is now evidence
that SDF-1 may signal through another chemokine receptor,
CXCR7/RDC1,25,26 but its role in cell trafficking and migra-
tion remains undefined.27,28
Molecular Pathways Associated with CXCR4/
SDF-1 Axis
Investigations into the mechanisms of CXCR4 activa-
tion have demonstrated that SDF-1 bound-CXCR4 acts via
Gi, to activate the phosphoinositol-3-kinase (PI3K)29 and
mitogen activated protein kinase (MAPK)30 signaling path-
ways (Figure 1). It has been suggested that the CXCR4/
SDF-1 complex is incorporated into lipid rafts, and may
associate with members of the Src family of kinases.31 Acti-
vated CXCR4 increases intracellular calcium mobilization
and induces phosphorylation of focal adhesion components
such as FAK and Pyk2.22,32–34 The PI3K/AKT and MAPK
signal transduction pathways contribute to chemotaxis, cell
migration,30,35 and secretion of various matrix metallopro-
teinases (MMP’s) including MMP-2 and MMP-9,34,36 which
are involved in the invasion of cells through the basement
membrane.37 They also induce expression of several cell
surface integrins such as VLA-4 and VLA-538–40 and secre-
tion of the angiopoietic factor, VEGF.41 Furthermore, block-
ing either the PI3K or MAPK pathway inhibits CXCR4
activated cell migration in a pre B cell line.30 Ultimately,
through these pathways, SDF1-bound CXCR4 can induce
cytoskeletal rearrangement, adhesion to endothelial cells,
polarized migration of cells to specific organs and the secre-
tion of angiopoietic factors, all important components of the
metastatic process.42–45
CXCR4 and SDF-1 Role in Cancer
Involvement of the CXCR4/SDF-1 axis in cancer is
attractive because it helps explain some of the well described
phenomena associated with metastasis. The two key compo-
nents of metastasis–acquisition of the capability to break
away from the primary tumor to become blood or lymph
borne and the subsequent ability to home in on its metastatic
destination-can both be influenced by the CXCR4/SDF-1
axis. The molecular changes described above confer on the
malignant cell a greater ability to migrate and invade,46,47
while the constitutive release by stromal cells from common
sites of metastasis such as bone marrow, lung, and liver, can
guide the circulating cell to home in on its metastatic desti-
nation.48 The role played by the CXCR4/SDF-1 axis in
leukocyte trafficking and homing of stem cells49,50 is likely
analogous to organ selective metastasis of cancer stem
cells.51 In this model, a cell’s metastatic potential will be
determined by surface CXCR4 expression while its destiny
will be influenced by local SDF-1 secretion at distal sites.
As such, the CXCR4/SDF-1 axis can help explain the
“nature” underlying metastatic tendency-CXCR4 expres-
sion-as well as the “nurture” of that tendency–SDF-1
secretion at metastatic sites.
The first evidence of a direct role for CXCR4/SDF-1 in
tumor metastasis came from a pivotal study by Muller et al.,52
which demonstrated that the most abundant of the chemokine
receptors in breast cancer was CXCR4. Specifically, CXCR4
expression was markedly up-regulated in breast cancer cells
compared with normal mammary epithelial cells in which
CXCR4 was undetectable. Furthermore, in vivo administra-
tion of an anti-CXCR4 monoclonal antibody markedly re-
FIGURE 1. Schematic illustrating
molecular pathways by which
CXCR4 acts. Stromal cell derived
factor (SDF-1) bound-CXCR4, possi-
bly after incorporation into lipid
rafts, acts via Gi, to activate the
phosphoinositol-3-kinase (PI3K) and
mitogen activated protein kinase
(MAPK) signaling pathways. Acti-
vated CXCR4 increases intracellular
calcium mobilization and induces
phosphorylation of focal adhesion
components such as FAK and Pyk2.
The activated signal transduction
pathways contribute to chemotaxis,
cell migration, and secretion of vari-
ous matrix metalloproteinases
(MMP’s) including MMP-2 and
MMP-9. Supporting references in
brackets.
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duced lung metastasis in a mouse model of breast cancer,
providing the first evidence that CXCR4 inhibition may be a
useful antimetastatic strategy. Subsequent studies have sug-
gested that the CXCR4/SDF-1 axis plays a role in the me-
tastasis of many types of tumor cells. Retrospective studies in
breast,47 especially triple negative breast cancer53 and other
cancers including nasopharyngeal54 and ovarian carcinomas55
have provided evidence that high expression of the CXCR4
receptor on primary tumor specimens correlates with a poorer
clinical outcome. In vitro studies54,56,57 in various tumor cell
lines have shown that inhibition of the CXCR4/SDF-1 che-
mokine axis results in decreased migration and invasion of
these cell lines. Lastly, in vivo studies have revealed that
inhibition of the CXCR4/SDF-1 axis significantly decreased
the amount of metastasis seen in mouse models of breast,52,58
renal,59 and head and neck cancers.60
Lung Cancer and the CXCR4/SDF-1 Axis
Increasing evidence suggests that the CXCR4/SDF-1
chemokine axis also plays a pivotal role in the metastasis of
lung cancer, particularly in NSCLC. Firstly, in vitro studies
have shown that NSCLC cell lines express high levels of
CXCR4 but not SDF-1 and that SDF-1-activated CXCR4
promotes migration and invasion of these cell lines in vitro.61
Interruption of this axis by CXCR4 down-regulation via
transfection with a CXCR4 antisense nucleotide fragment, or
by incubating cells with a CXCR4 neutralizing antibody,
significantly decreases migration, invasion, and adhesion of
NSCLC cell line cells in vitro.62 Secondly, in vivo studies
using a SCID mouse model of heterotopic or orthotopic
xenoengraftment of human NSCLC cells show that preferen-
tial sites of lung cancer metastases have significantly higher
levels of SDF-1 protein expression than the primary tumor or
plasma levels61 suggesting that a chemotactic gradient may
be established between the site of the primary tumor and
metastatic sites. In vivo neutralization of SDF-1 by an anti-
SDF-1 or anti-CXCR4 monoclonal antibody resulted in a
significant decrease of NSCLC metastases to several organs
including the adrenal glands, liver, lung, brain, and bone
marrow.22,61 Importantly, this is supported by retrospective
clinical studies that show a correlation between primary
tumor CXCR4 expression and clinical outcome in NSCLC
patients. Patients with high CXCR4 expressing tumors seem
more prone to metastasis than patients with low expressing
tumors.62 When CXCR4 expression is limited to the nucleus
only, this correlation is lost and a better prognosis is seen
clearly suggesting that the metastatic potential is conferred by
presumed membrane localization of the receptor.63 Taken
together, these studies provide a sound rationale for pursuing
anti-CXCR4/SDF-1 approaches in clinical trials.
Anti-CXCR4 Strategies in Clinical Trials
Given the accumulating evidence supporting a role for
the CXCR4/SDF-1 axis in NSCLC it is not surprising that
attention is now focusing on it as a therapeutic target. Al-
though disruption of the CXCR4/SDF-1 axis has been ex-
plored in HIV treatment, there is a dearth of experience using
this approach in the oncology world. Several CXCR4 inhib-
itors have been tested in preclinical studies to assess their
efficacy in preventing the growth and spread of various tumor
cell types, but only recently have these agents entered into
clinical trials. Two of these deserve a mention. AMD 3100 is
a small molecule specific antagonist of the CXCR4 receptor
which competitively binds and prevents the interaction of the
receptor with SDF-1. A recent clinical trial showed that the
administration of AMD 3100 in combination with granulo-
cyte colony-stimulating factor to patients with non-Hodgkin
lymphoma or multiple myeloma significantly increased the
mobilization of hematopoietic progenitor cells to be used for
autologous transplantation.64 That this approach can influence
the distribution of progenitor cells in vivo is a very significant
proof of principle. Another agent, CTCE-9908, a small pep-
tide CXCR4 antagonist, is well tolerated and preliminary
evidence from phase I/II clinical trials with 26 patients,
including 3 lung cancer patients, indicate that this agent is
efficacious in late stage solid tumors.65 To date there are no
other published trials of this approach in early or metastatic
disease. There have been no trials of anti-CXCR4 or anti-
SDF-1 monoclonal antibodies and no trials as yet of CXCR4
antisense approaches.
CONCLUSION
Paget’s concept of seed and soil implies that a number
of factors involving both the “nature” of the malignant cell
and the “nurture” provided by the distal environment must
collaborate to allow metastasis to occur. Clearly, chemokines
and their receptors provide a molecular explanation for this
“seed and soil” phenomenon. The increasing evidence sup-
porting a role for the CXCR4/SDF-1 axis in the metastatic
evolution of several cancers, and especially NSCLC, provides
the rationale for targeted disruption of this axis in future
clinical trials. Because of its well-defined role as a portal of
entry for the HIV, a number of inhibitors of this axis have
already been developed and may be promptly tested in
preclinical models and clinical trials. It is very likely that the
detailed understanding of the role of the CXCR4/SDF-1 axis
in NSCLC will lead to new treatment strategies that may
allow us to more meaningfully change the clinical course of
this disease in the very near future.
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